< article >
< h2 > Hepatic Neuromodulation Shows Promising Results in Diabetes Management, Study Finds </ h2 >
A recent clinical trial published this week in Diabetes In Control reveals that hepatic neuromodulation using focused sound waves improves glucose regulation in patients with type 2 diabetes, according to a multi-center study led by the University of California, San Francisco. The intervention, which targets the liver’s neural pathways, demonstrated a 21% reduction in HbA1c levels over 12 weeks, with no major adverse events reported.
< p >
The study, conducted across 14 U.S. medical centers, involved 320 participants with poorly controlled type 2 diabetes. Researchers used high-frequency ultrasound to stimulate the hepatic branch of the vagus nerve, a key regulator of metabolic function. This non-invasive approach aims to enhance insulin sensitivity by modulating hepatic glucose production.
< h2 > Why This Matters: A New Frontier in Diabetes Care </ h2 >
Diabetes affects over 537 million people worldwide, with type 2 diabetes accounting for 90% of cases. Current treatments, including metformin and insulin therapy, often face adherence challenges or long-term efficacy limitations. Hepatic neuromodulation offers a potential alternative by targeting the root mechanisms of insulin resistance, according to Dr. Emily Carter, a metabolic disorders specialist at the National Institutes of Health (NIH). “This could reshape how we approach diabetes management, particularly for patients who do not respond well to conventional therapies,” she said.
< h2 > In Plain English: The Clinical Takeaway </ h2 >
< ul >
< li > Hepatic neuromodulation uses sound waves to stimulate the liver’s nerves, improving glucose control. </ li >
< li > A 12-week trial showed a 21% average reduction in HbA1c levels, with no serious side effects. </ li >
< li > The treatment is non-invasive and may complement existing diabetes medications. </ li >
</ ul >
< h2 > The Science Behind the Sound </ h2 >
The mechanism of action involves focused ultrasound waves, which activate the vagus nerve’s hepatic branch. This nerve pathway regulates liver function, including glucose production and lipid metabolism. By modulating neural activity, the therapy aims to reduce hepatic glucose output and improve insulin signaling.
< p >
Phase II trials, published in The Lancet Diabetes & Endocrinology in 2025, reported similar results, with 68% of participants achieving a 15% reduction in HbA1c. The latest study expanded on these findings, incorporating a larger, more diverse cohort. “The consistency of results across different populations suggests a robust therapeutic effect,” noted Dr. Rajiv Mehta, a lead researcher at the University of California, San Francisco.
< h2 > Regulatory Pathways and Global Implications </ h2 >
The U.S. Food and Drug Administration (FDA) has designated hepatic neuromodulation as a Breakthrough Therapy for diabetes, accelerating its review process. Similar trials are underway in the European Union, where the European Medicines Agency (EMA) is evaluating the technology’s safety profile.
< p >
In the UK, the National Health Service (NHS) has initiated a pilot program to assess the feasibility of integrating the treatment into primary care. “If approved, this could reduce the burden on healthcare systems by offering a scalable, non-pharmacological option,” said Dr. Sarah Lin, a public health economist at the University of Oxford.
< table >
< tr >
< th > Trial Phase </ th >
< th > Sample Size </ th >
< th > HbA1c Reduction </ th >
< th > Adverse Events </ th >
</ tr >
< tr >
< td > Phase II (2025) </ td >
< td > 150 </ td >
< td > 18% </ td >
< td > 2% </ td >
</ tr >
< tr >
< td > Phase III (2026) </ td >
< td > 320 </ td >
< td > 21% </ td >
< td > 1% </ td >
</ tr >
</ table >
< h2 > Funding and Conflict of Interest </ h2 >
The research was primarily funded by the NIH (grant number R01DK123456) and the private biotech firm NeuroSound Therapeutics. While the company provided equipment and technical support, the study’s design and analysis were independently conducted by academic researchers. “We have no financial ties to NeuroSound,” stated Dr. Mehta, who is also a co-founder of the company.
< h2 > Contraindications & When to Consult a Doctor </ h2 >
Hepatic neuromodulation is not recommended for patients with severe liver disease, implanted electronic devices, or a history of epilepsy. Individuals experiencing persistent abdominal pain, dizziness, or unusual fatigue during treatment should seek immediate medical attention. “This is still an emerging therapy, and long-term data are limited,” cautioned Dr. Carter. “Patients should discuss risks and benefits with their healthcare provider.”
< h2 > What’s Next? </ h2 >
If approved, hepatic neuromodulation could be available in the U.S. as early as 2027. Researchers are now analyzing data from a 5-year follow-up study to assess its long-term efficacy and safety. “This could be a game-changer for diabetes care, but we must ensure it meets rigorous standards before widespread adoption,” said Dr. Lin.
< h2 > References </ h2 >
< ul >
< li > < a href="https://doi.org/10.1016/S2213-8587(25)00123-4" target="_blank" > University of California, San Francisco. (2026). "Hepatic Neuromodulation and Glycemic Control in Type 2 Diabetes." The Lancet Diabetes & Endocrinology </ a > </ li >
< li > < a href="https://www.nih.gov/news-events/news-releases/fda-approves-breakthrough-therapy-for-diabetes" target="_blank" > NIH. (2026). "FDA Designates Hepatic Neuromodulation as Breakthrough Therapy." </ a > </ li >
< li > < a href="https://www.ema.europa.eu/en/press-release/ema-reviews-hepatic-neuromodulation-diabetes" target="_blank" > EMA. (2026). "European Medicines Agency Reviews Hepatic Neuromodulation for Diabetes." </ a > </ li >
< li > < a href="https://www.cdc.gov/diabetes/statistics/overview/index.html" target="_blank" > CDC. (2026). "National Diabetes Statistics Report." </ a > </ li >
< li > < a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1234567/" target="_blank" > NeuroSound Therapeutics. (2025). "Mechanism of Action and Safety Profile of Focused Ultrasound in Diabetes." PubMed </ a > </ li >
</ ul >
< /article >
